Call us today 212-583-0100

ENZO Biochem Is Well Positioned For New Paradigms In Biotech and Healthcare, Annual Meeting Is Told Company Nominees for Class I Directors Approved By Shareholders

NEW YORK, NY, January 29, 2010 --- Enzo Biochem, Inc. (NYSE: ENZ) is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsidiaries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.
 “This past year was one of significant progress and transformation,” Mr. Weiner said.  “Each of our Company’s major areas of interest – life science, diagnostics and therapeutics – is responding to focused planning aimed at enhancing results and growing their activities. Our cash position remains strong and our program positioning Enzo for the new paradigms in biotechnology and healthcare are very promising.”
Mr. Weiner noted that Enzo today has more than 650 employees, is generating revenues in excess of $100 million annually, operates globally in its Life Science division and has begun to reap the benefits of expanded facilities and a growing roster of esoteric and genetic testing at Enzo Labs, its diagnostic unit serving physicians throughout the New York metropolitan region.
Enzo Therapeutics, which Mr. Weiner referred to as the “venture arm” of the Company, has under development multiple immune regulation therapies in such areas as gastrointestinal, infectious and ophthalmic diseases, in addition to monetizing proprietary modalities, he added.   “Our history, going back over 30 years, has been one of innovation and development involving the use of nucleic acids as informational molecules and the use of compounds for immune modulation, and we believe these innovations and their related patents have much value which we plan to unlock,” Mr. Weiner stated.
Shareholders at the meeting elected three Class I directors – Irwin C. Gerson, Gregory M. Bortz and Dr. Stephen B. H. Kent.  They also ratified the accounting firm of Ernst & Young LLP to serve as the Company’s independent auditors for the fiscal year ending July 31, 2010.
About Enzo
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community.  Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field.  Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 40,000 products serve the molecular biology, drug discovery and pathology research markets worldwide.  Enzo Clinical Labs division provides laboratory services for a growing roster of physicians in the New York Metropolitan area, as well as parts of New Jersey and Pennsylvania.  Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics.  Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics.  Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.  It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects.  In the course of the company’s research and development activities, Enzo has developed a substantial portfolio of intellectual property assets, with 249 issued patents worldwide and over 200 pending patent applications.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
     For: Enzo Biochem, Inc.
     Steven Anreder, 212-532-3232       or    Michael Wachs, CEOcast, Inc., 212-732-4300